Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Vertex remains focused on diversifying its product portfolio and recently launched two new approved therapies: Alyftrek and ...

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

Journavx is a medicine for acute pain -- though there are lots of options here, most are opioid-based ones. Journavx became the first non-opioid oral pain inhibitor to earn the green light from ...